GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (NAS:AXDX) » Definitions » Piotroski F-Score

Accelerate Diagnostics (Accelerate Diagnostics) Piotroski F-Score : 3 (As of Apr. 26, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Accelerate Diagnostics Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Accelerate Diagnostics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Accelerate Diagnostics's Piotroski F-Score or its related term are showing as below:

AXDX' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 5
Current: 3

During the past 13 years, the highest Piotroski F-Score of Accelerate Diagnostics was 5. The lowest was 2. And the median was 3.


Accelerate Diagnostics Piotroski F-Score Historical Data

The historical data trend for Accelerate Diagnostics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerate Diagnostics Piotroski F-Score Chart

Accelerate Diagnostics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 2.00 3.00 5.00 3.00

Accelerate Diagnostics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 4.00 4.00 4.00 3.00

Competitive Comparison of Accelerate Diagnostics's Piotroski F-Score

For the Medical Devices subindustry, Accelerate Diagnostics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accelerate Diagnostics's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Accelerate Diagnostics's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -16.795 + -32.735 + 0.91 + -12.998 = $-61.62 Mil.
Cash Flow from Operations was -13.367 + -10.821 + -8.253 + -7.755 = $-40.20 Mil.
Revenue was 2.812 + 2.921 + 3.299 + 3.027 = $12.06 Mil.
Gross Profit was 1.011 + 0.799 + 0.107 + 0.633 = $2.55 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(65.015 + 51.002 + 49.878 + 39.324 + 31.366) / 5 = $47.317 Mil.
Total Assets at the begining of this year (Dec22) was $65.02 Mil.
Long-Term Debt & Capital Lease Obligation was $36.93 Mil.
Total Current Assets was $24.47 Mil.
Total Current Liabilities was $12.03 Mil.
Net Income was -13.465 + -18.523 + -15.896 + -14.609 = $-62.49 Mil.

Revenue was 2.958 + 3.861 + 2.96 + 2.972 = $12.75 Mil.
Gross Profit was 0.802 + 1.08 + 0.579 + 0.841 = $3.30 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(83.047 + 70.357 + 58.726 + 75.847 + 65.015) / 5 = $70.5984 Mil.
Total Assets at the begining of last year (Dec21) was $83.05 Mil.
Long-Term Debt & Capital Lease Obligation was $19.19 Mil.
Total Current Assets was $56.01 Mil.
Total Current Liabilities was $66.56 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Accelerate Diagnostics's current Net Income (TTM) was -61.62. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Accelerate Diagnostics's current Cash Flow from Operations (TTM) was -40.20. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-61.618/65.015
=-0.94775052

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-62.493/83.047
=-0.7525016

Accelerate Diagnostics's return on assets of this year was -0.94775052. Accelerate Diagnostics's return on assets of last year was -0.7525016. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Accelerate Diagnostics's current Net Income (TTM) was -61.62. Accelerate Diagnostics's current Cash Flow from Operations (TTM) was -40.20. ==> -40.20 > -61.62 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=36.934/47.317
=0.78056512

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=19.185/70.5984
=0.27174837

Accelerate Diagnostics's gearing of this year was 0.78056512. Accelerate Diagnostics's gearing of last year was 0.27174837. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=24.466/12.034
=2.03307296

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=56.014/66.557
=0.84159442

Accelerate Diagnostics's current ratio of this year was 2.03307296. Accelerate Diagnostics's current ratio of last year was 0.84159442. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Accelerate Diagnostics's number of shares in issue this year was 14.577. Accelerate Diagnostics's number of shares in issue last year was 9.749. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2.55/12.059
=0.21146032

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=3.302/12.751
=0.25896008

Accelerate Diagnostics's gross margin of this year was 0.21146032. Accelerate Diagnostics's gross margin of last year was 0.25896008. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=12.059/65.015
=0.18548027

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=12.751/83.047
=0.15353956

Accelerate Diagnostics's asset turnover of this year was 0.18548027. Accelerate Diagnostics's asset turnover of last year was 0.15353956. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+1+0+0+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Accelerate Diagnostics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Accelerate Diagnostics  (NAS:AXDX) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Accelerate Diagnostics Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Accelerate Diagnostics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Accelerate Diagnostics (Accelerate Diagnostics) Business Description

Traded in Other Exchanges
Address
3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.
Executives
David Patience officer: Chief Financial Officer C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 240, TUCSON AZ 85714
Jack Phillips director, officer: PRESIDENT AND CEO 11731 YALE DR, CARMEL IN 46032
Larry Michael Mertz officer: Chief Technology Officer 3950 S. COUNTRY CLUB ROAD, TUCSON AZ 85714
Marran H. Ogilvie director 599 LEXINGTON AVENUE, NEW YORK NY 10022
Jennifer Regan director C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Mark S. Black director 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Steven Reichling officer: CFO 7000 NORTH BROADWAY, BUILDING 3-307, DENVER CO 80221
Ron Price officer: SVP & HEAD OF COM OPS AMERICAS 3950 SOUTH COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Wayne Burris director 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Hany Massarany director 1910 INNOVATION PARK DR, TUCSON AZ 85737
Jack W Schuler director, 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Mark C Miller director C/O STERICYCLE INC., 28161 N KEITH DRIVE, LAKE FOREST IL 60045
Ten Brink Frank Jm director C/O STERICYCLE INC, 28161 N KEITH DR, LAKE FOREST IL 60045
Charles M Watts director 3950 SOUTH COUNTRY CLUB, SUITE 470, TUCSON AZ 85714
Louise Francesconi director 870 WINTER STREET, WALTHAM MA 02451

Accelerate Diagnostics (Accelerate Diagnostics) Headlines

From GuruFocus